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Introduction
The search for new estrogen-regulated genes in guinea pig cells 
performed within our laboratory resulted in the discovery of 
a new gene called gec1 (glandular epithelial cell 1).1 Later work 
showed that this new gene is also expressed in human cells and 
shares a high homology with a gene named gabarap (GABA
A
 
receptor-associated protein).2 The two proteins present an almost 
identical primary sequence (86% identity) and share common 
features such as their small size (117 amino-acids) and their abil-
ity to bind tubulin and GABA
A
 receptors.3,4 Accordingly, GEC1 
was classified as a GABARAP-like 1 protein (GABARAPL1) and 
was described to play a role in intracellular GABA
A
 receptor traf-
ficking. The GABARAP family is composed of several members 
which share a high identity and an almost identical three-dimen-
sional structure.5 The five identified members of this family are: 
GABARAP, GABARAPL1, MAP-LC3 (light chain 3 of micro-
tubule associated protein), GATE-16 (Golgi-associated ATPase 
GABARAPL1 (GEC1) associates  
with autophagic vesicles
Fatima Zahra chakrama, stéphanie seguin-Py, Jaclyn Nicole Le Grand, Annick Fraichard, Régis Delage-Mourroux, 
Gilles Despouy, Valérie Perez, Michèle Jouvenot and Michaël Boyer-Guittaut*
Université de Franche-comté; Laboratoire de Biochimie; eA3922 “estrogènes, expression Génique et Pathologies du système Nerveux central”; iFR133; 
U.F.R. sciences et Techniques; Besançon, France
Key words: GEC1, GABARAPL1, GABARAP, LC3, autophagy, lysosome, HEK293, MCF-7
Abbreviations: Atg, autophagy-related; DMSO, dimethylsulfoxyde; EBSS, Earle’s balanced salt solution; FBS, fetal bovine serum; 
GABA
A
, γ-aminobutyric acid, type A; GABARAP, GABA
A
 receptor-associated protein; GABARAPL1, GABARAPL2, GABA
A
 
receptor-protein-like 1 and 2; GATE-16, Golgi-associated ATPase enhancer of 16 kDa; GEC1, glandular epithelial cell protein 1; 
GFP, green fluorescent protein; HEK293, human embryonic kidney 293; MAP-LC3, microtubule-associated protein light chain 
3; MCF-7, Michigan Cancer Foundation-7; MEFs, mouse embryonic fibroblasts; NH
4
Cl, ammonium chloride; PBS, phosphate 
buffer saline; PFA, paraformaldehyde; PMSF, phenylmethylsulfonidefluoride; PVDF, polyvinylidene difluoride; SDS, sodium 
dodecylsulfate; SDSLB, SDS loading buffer; SDS-PAGE, SDS polyacrylamide gel electrophoresis; TEMED, N’, N’, N’, N’-
tetramethyl ethylenediamine
enhancer of 16 kDa or GABARAPL2) and the yeast protein Atg8 
(Autophagy-related protein 8).
Members of the GABARAP family have been studied mainly 
for their implication in protein and vesicle intracellular transport 
due to their reported interaction with the cytoskeleton. It has also 
been established, however, that GABARAP is involved in cell 
proliferation, programmed cell death and tumorigenesis6-8 and 
that Atg8, GATE-16, GABARAP and MAP-LC3 (LC3) are all 
involved in the formation and elongation of autophagic vesicles 
called autophagosomes.9
Macroautophagy, hereafter referred to simply as autophagy, 
is a protein and organelle degradation pathway, first discovered 
in yeast, allowing the recycling of intracellular molecules during 
stress conditions such as nutrient or oxygen deprivation.10 This 
cellular phenomenon has been described to play a major role dur-
ing physiological processes such as neurodegenerative diseases, 
cardiomyopathies, cancer, programmed cell death and bacte-
rial and viral infections.11-13 During this process, a cup-shaped 
Gabarapl1 (gec1) was first described as an estrogen-regulated gene which shares a high sequence homology with the 
gabarap gene. We previously demonstrated that GABARAPL1, like GABARAP, interacts with the GABAA receptor and 
tubulin and promotes tubulin polymerization. Previous work has demonstrated that the GABARAP family members 
(GABARAP, Lc3, GATe-16 and Atg8) are not only involved in the transport of proteins or vesicles but are also implicated in 
various mechanisms such as autophagy, cell death, cell proliferation and tumor progression. We therefore asked whether 
GABARAPL1 might also play a role in autophagy. First, we showed that GABARAPL1 is cleaved at glycine 116, a residue 
which is conserved in other members of the family. We also demonstrated that GABARAPL1 is linked to phospholipids, 
delipidated by Atg4B, associated with intracellular membranes and accumulated in intracellular vesicles after inhibition of 
lysosomal activity. Finally, we showed that GABARAPL1 partially colocalizes with Lc3 or Lysotracker green in intracellular 
vesicles. Taken together, our results demonstrate that GABARAPL1 associates with autophagic vesicles.
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in the cells and the corresponding lysate probed with the anti-
GFP antibody, we observed only one signal, corresponding to the 
truncated GFP protein, below the 29 kDa marker (Fig. 1A, lane 
3). The difference in size between the native GFP, 29 kDa in 
size (lane 1), and the cleaved GFP (lane 3) was due to the pres-
ence of a supplementary linker sequence present in the pEGFP-
C1 commercial vector. We confirmed these results by probing 
with the anti-GABARAPL1 antibody which produced only one 
signal at 16 kDa (Fig. 1A, lane 7). These data demonstrate that 
the GABARAPL1-GFP protein is cleaved in the cells into two 
peptides, GFP and GABARAPL1. To investigate whether the 
glycine 116 was the site of cleavage in GABARAPL1, we cre-
ated a vector encoding the GABARAPL1-G116A-GFP protein, 
a mutant protein in which the Gly116 is replaced by an alanine 
(Fig. 1B). This mutation has previously been shown to inhibit 
the cleavage of autophagic effectors of the GABARAP family 
including GABARAP and LC3.17,29 When the GABARAPL1-
G116A-GFP protein was expressed in HEK293 cells, we detected 
a signal at the expected size of 44 kDa, corresponding to the 
fusion protein (Fig. 1A, lanes 4 and 8). These results demonstrate 
that a single point mutation (G116A) inhibits the cleavage of the 
GABARAPL1 protein in the cells.
GABARAPL1 is modified during the autophagic process. 
Previous work reported that several autophagic effectors (LC3, 
GABARAP, GATE-16) are linked to phospholipids during the 
course of autophagy to lead to a modified form of these factors, 
denoted by the suffix “-II”.18 This modification status is easily 
detected by western blotting since the modified phospholipid-
linked protein migrates faster than the mature form on SDS-
PAGE. To assess if GABARAPL1 is linked to phospholipids in 
the cells and exists as the modified protein GABARAPL1-II, we 
used a HEK293 stable cell line expressing the GABARAPL1 pro-
tein fused to the Flag epitope at its N-terminus and six histidine 
residues at its C-terminus, Flag:GABARAPL1:6 his.
To enrich and detect the modified form of Flag:GABARAPL1:6 
his (Flag:GABARAPL1-II), we induced and/or blocked the 
autophagic flux by using different chemical compounds: either 
inhibitors of lysosomal activity [Bafilomycin A1, a specific inhib-
itor of the vacuolar type H+-ATPase (V-ATPase) or NH
4
Cl, a 
V-ATPase-independent neutralyzer of lysosomal pH],30 inhibi-
tors of lysosomal enzyme activity (E64d and PepstatinA, cal-
pain and cathepsins B, D and E inhibitors)26 or inducers of 
autophagy (Rapamycin, an inhibitor of the mTOR kinase and 
EBSS, a starvation medium).31 By inducing and/or blocking the 
autophagic pathway, we expected to observe an accumulation 
of autophagosomes and therefore an increase in the levels of the 
Flag:GABARAPL1-II form of the protein.
When untreated HEK293-Flag:GABARAPL1:6his cell 
lysates were probed with an antibody against GABARAPL1, we 
detected two signals at 16 and 19 kDa (Fig. 2A and B, lanes 1), 
corresponding to the mature GABARAP-I and GABARAPL1-I 
proteins. This can be explained by the fact that no commercial 
or homemade antibody which we have tested so far has been 
able to differentiate between the two homologous proteins.3,32 
Moreover, previous transient transfection experiments using 
GABARAP and GABARAPL1-expressing vectors showed that 
membrane sac (pre-autophagosome) expands to engulf cytoso-
lic components and finally closes to form an autophagosome. 
The autophagosome then fuses with the lysosome leading to the 
proteolytic degradation of its content. These two structures are 
characterized by different molecular markers: Atg5 modifica-
tion by Atg12 is linked to the formation of pre-autophagosomes 
and the cleavage and covalent lipidation of LC3 is a marker of 
autophagosomes.14
During autophagy, the covalent link between phospholipids 
and effector proteins occurs through a process similar to that 
described for Ubiquitin and SUMO-1 (Small Ubiquitin-like 
MOdifier 1).15 This mechanism and the enzymes involved were 
first described in yeast but homologous proteins have since been 
identified in mammals.16 First, one or several amino acids at the 
C-terminal end of the precursor protein are cleaved, thanks to 
a maturation enzyme (Atg4 family), to free a glycine residue 
(Gly120 in LC3,17 or Gly116 in GATE-16 and GABARAP18). 
This first step leads to the mature form of the protein, denoted by 
the suffix “-I”. The mature protein is then transferred onto phos-
pholipids via the intervention of an activating enzyme (E1-like, 
Atg7)19 and a conjugating enzyme (E2-like, Atg3)20 to yield the 
phospholipid-linked protein, denoted by the suffix “-II”. This 
process is cyclic since the effectors can be released thanks to a 
delipidating enzyme (Atg4 family) which breaks the covalent 
bond between the protein and the lipid.21 Since GABARAPL1 
shares a high homology with the GABARAP family members 
and the glycine 116 residue, essential for the autophagic process, 
is conserved in this protein, we asked whether GABARAPL1 
might be implicated in the autophagic process as well.
Here we report data demonstrating that GABARAPL1 is 
cleaved at glycine 116 in the cell types tested and is only detect-
able as the processed mature form of the protein (-I). We also 
show that GABARAPL1 is linked onto phospholipids to gener-
ate a modified form of the protein (-II) and demonstrate that 
it associates with autophagosomes or lysosomes in the cells. 
Therefore, our work describes, for the first time, the implication 
of GABARAPL1 in autophagy.
Results
GABARAPL1 is cleaved in cells at the glycine 116 residue to 
produce a mature form of the protein. Since it has been pre-
viously reported that some effectors of autophagy such as LC3, 
GATE-16 and GABARAP undergo a necessary maturation step 
before their involvement in the autophagic process and that 
GABARAPL1 shares a high identity with these proteins, we 
hypothesized that GABARAPL1 may also undergo cleavage to 
free the glycine 116 (Gly116) and produce the mature form of the 
protein, GABARAPL1-I.
To do so, we designed two different vectors encoding GFP 
fused to the N-terminus of GABARAPL1 (GFP-GABARAPL1) 
or the C-terminus of GABARAPL1 (GABARAPL1-GFP). When 
these proteins were expressed in HEK293 cells, we detected the 
GFP-GABARAPL1 protein at the expected size of 44 kDa using 
either the GFP or GABARAPL1 antibody (Fig. 1A, lanes 2 and 
6). However when the GABARAPL1-GFP protein was expressed 
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actors such as GABARAP and LC3 (Fig. 2A and B) except 
that the ratio LC3-II/LC3-I was always higher than the ratio 
GABARAPL1-II/GABARAPL1-I. All together, these results 
demonstrate that GABARAPL1 is modified in the cells during 
the autophagic process and that the amount of the modified form 
-II is regulated by autophagy inducers and lysosomal degradation 
inhibitors.
Atg4B delipidates GABARAPL1 in the cells. The cellu-
lar autophagic process is a cyclic mechanism and the proteins 
involved in this pathway are recycled for later rounds. In par-
ticular, the proteins linked to the phospholipids which form the 
autophagosomes can be reused if they are not degraded in the 
lysosome. To be recycled, these proteins need to be released from 
the lipids via the intervention of an autophagy-related cysteine 
protease (Atg4). Several of these enzymes have been described in 
mammals but one in particular has been described to be involved 
in the maturation and the recycling of the GABARAP family 
members: Atg4B.21
To assess whether Atg4B was also involved in the recycling of 
the GABARAPL1 protein and investigate the nature of the mod-
ification, we transiently transfected an Atg4B-expressing vector 
in HEK293-Flag:GABARAPL1:6 his cells. Afterwards, we used 
an anti-GABARAPL1 antibody to detect the GABARAPL1 pro-
tein and its modified forms in cell extracts. As shown in Figure 
3 (lanes 1, 2 and 3), the cells which did not overexpress the 
Atg4B protein displayed similar results to the ones previously 
GABARAP migrates as a 16 kDa protein and GABARAPL1 as a 
19 kDa protein on SDS-PAGE (data not shown). GABARAP was 
therefore used in our assays as an internal control to follow the 
behavior of a previously described autophagy effector.33 HEK293-
Flag:GABARAPL1:6 his cells were then cultured in the presence 
of lysosome or lysosomal enzyme inhibitors (NH
4
Cl, Bafilomycin 
A1 or E64d/PepstatinA),27,34 or autophagy inducers (EBSS or 
Rapamycin) or combinations of both. The GABARAPL1 protein 
was then detected in the cell lysates by immunoblotting (Fig. 2A 
and B). In HEK293-Flag:GABARAPL1:6 his cells treated with 
lysosomal activity inhibitors alone (NH
4
Cl, Bafilomycin A1 or 
E64d/PepstatinA), we detected the apparition of two new sig-
nals, migrating faster than the unmodified proteins, which cor-
responded to modified forms of GABARAP (GABARAP-II) and 
GABARAPL1 (GABARAPL1-II) (Fig. 2A, lanes 2 and 3 and 
B, lane 2). After treatment of HEK293-Flag:GABARAPL1:6 
his cells with autophagy inducers (EBSS and Rapamycin), we 
observed no increase in the amount of the forms -II in the cells 
(Fig. 2A, lanes 4 and 5 and B, lanes 3 and 4). However, when 
we incubated the HEK293-Flag:GABARAPL1:6 his cells with a 
combination of autophagy inducers and lysosomal activity inhib-
itors, we observed a stronger increase in the amount of forms -II 
of both proteins compared to the inducers or inhibitors alone 
(Fig. 2A, lanes 6 and 7 and B, lanes 5 and 6). Moreover, we 
observed that, in our model, the behavior of GABARAPL1 was 
similar to the previously described behavior of known autophagy 
Figure 1. GABARAPL1 is cleaved in cells at the glycine 116 residue to produce a mature form of the protein. (A) heK293 cells were transfected with the 
peGFP-c1, pGFP-GABARAPL1, pGABARAPL1-GFP, pGABARAPL1-G116A-GFP, vectors. After 48 h, cells were lysed and total proteins were separated on 
15% sDs-PAGe and immunoblotted using anti-GFP or anti-GABARAPL1 antibodies and the ecL Plus reagent. Vertical lines have been inserted to indi-
cate repositioned lanes. A representative experiment of 5 performed is shown. (B) schema representing the GABARAPL1-GFP and GABARAPL1-G116A-
GFP fusion proteins and the peptides formed after their expression and maturation in cells.
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described in the Figure 2. On the contrary, when 
the Atg4B protein was overexpressed in these cells, 
we detected an important decrease in the amount 
of the Flag:GABARAPL1-II form of the protein 
in the cells treated with NH
4
Cl and Bafilomycin 
A1 (Fig. 3, lanes 5 and 6) compared to the lev-
els observed in the cells which do not overexpress 
Atg4B (Fig. 3, lanes 2 and 3). We also observed 
that the levels of GABARAP-II were decreased 
after Atg4B overexpression. The latter data dem-
onstrate that the autophagy-related cysteine pro-
tease Atg4B delipidates the GABARAPL1 protein 
to allow its further recycling and confirm that 
GABARAPL1 is linked onto phospholipids in the 
cells.
The GABARAPL1-II form is associated 
with membranes in the cells. To determine 
whether the lipidated form of GABARAPL1 
(GABARAPL1-II) is associated with intracellular 
membranes, we used a cell fractionation protocol 
to separate the membrane and soluble fractions of 
the cells.28 This protocol was applied to HEK293-
Flag:GABARAPL1:6 his cells grown in complete 
medium or DMEM supplemented with 1% SVF 
and NH
4
Cl for 2 h. Cell homogenates (Whole Cell 
Lysates, WCL) were then centrifuged at 100,000 
g and the resulting supernatant and pellet were 
analyzed by immunoblotting using GABARAPL1 
and Transferrin receptor (CD71) antibodies. The 
Transferrin receptor was used as a control for cell 
fractionation as it has been previously described 
to be associated with the intracellular membrane 
Figure 2. GABARAPL1 is conjugated to phospholipids 
in the cells. heK293-Flag:GABARAPL1:6 his cells were 
cultured in the presence or absence of autophagy 
inducers (10 µM Rapamycine or eBss for 4 h) with or 
without (A) a lysosome inhibitor (200 nM Bafilomycin 
A1 for 16 h) or (B) lysosomal enzyme inhibitors (10 µg/
ml e64d/PepstatinA). incubation with an inhibitor 
of lysosomal acidity (50 mM Nh4cl for 2 h) was used 
as a positive control in the (A). cells were then lysed 
and total proteins were separated on 15% sDs-PAGe 
followed by immunoblotting with anti-GABARAPL1, 
anti-Lc3 and anti-Actin antibodies and the ecL Plus re-
agent. A representative experiment of five performed 
is shown.
Figure 3. Atg4B delipidates GABARAPL1 in the cells. 
heK293-Flag:GABARAPL1:6 his cells were transfected 
with a control (pcDNA3.1) or an Atg4B-expressing 
vector (psF1-Flag(3X):hsAtg4B:Myc:6 his). 48 h after 
transfection, cells were cultured in 50 mM Nh4cl for 2 h 
or 500 nM Bafilomycin A1 for 24 h. cells were then lysed 
and total proteins were separated on 15% sDs-PAGe 
followed by immunoblotting with anti-GABARAPL1, 
anti-Actin and anti-Atg4B antibodies and detection 
with the ecL Plus reagent. Vertical lines have been in-
serted to indicate repositioned lanes. A representative 
experiment of three performed is shown.
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fraction.28 Our results showed that NH
4
Cl induced the 
apparition of the GABARAP-II and GABARAPL1-II 
forms in the cells (Fig. 4, lane 4, WCL) as described 
above (Fig. 2). Following cell fractionation, the 
mature proteins (-I) were predominantly detected in 
the supernatants of the untreated and treated cells 
(Fig. 4, lanes 2 and 5). Conversely, the lipidated forms 
(-II) were enriched in the pellet (membraneous frac-
tion) of the induced cells (Fig. 4, lane 6). No form -II 
was detected in the pellet obtained from the untreated 
cells (Fig. 4, lane 3). Moreover, the Transferrin recep-
tor was detected predominantly in the pellets dem-
onstrating the specific enrichment of membranes in 
these fractions. All together, our results show that the 
GABARAPL1-II form is associated with intracellular 
membranes in the cells.
Inhibition of lysosomal activity results in the accu-
mulation of GABARAPL1-positive intracytoplasmic 
vesicles. Thus far, we have shown that GABARAPL1 
is modified in the cells, is delipidated by Atg4B, and 
that the modified form is enriched in intracellular 
membrane fractions. To confirm that GABARAPL1 
is in fact associated with autophagosomes, we inves-
tigated the intracellular distribution of this protein 
after the inhibition of the autophagic flux. Indeed, we 
already know that proteins linked to autophagic vesi-
cles display a punctate cytoplasmic distribution, corre-
sponding to their localization into autophagosomes.23 
As such, we first designed a MCF-7 stable cell line expressing 
the DsRed-GABARAPL1 protein, then we inhibited lysosomal 
activity in these cells. In the untreated DsRed-GABARAPL1 
cell lines, the fusion protein was detected in punctate locations 
throughout the cytosol (Fig. 5A and D). When the MCF7-DsRed-
GABARAPL1 cells were treated with NH
4
Cl (Fig. 5B and E), we 
detected a slight increase in the number of intracellular DsRed-
GABARAPL1-positive vesicles. When the DsRed-GABARAPL1 
cells were treated with Bafilomycin A1, we detected an increase 
in the number of GABARAPL1-positive vesicles but more strik-
ingly, we observed a total relocalization of these vesicles in a clus-
ter on one side of the nucleus (Fig. 5C and F). Such a pattern has 
been previously described for the localization of the lysosomes in 
the cell.30 In conclusion, GABARAPL1 is localized in intracyto-
plasmic vesicles, a localization which is increased after treatment 
with lysosomal activity inhibitors.
GABARAPL1 partially colocalizes with GFP-LC3 or 
Lysotracker green in intracytoplasmic vesicles. To determine the 
nature of the DsRed-GABARAPL1-containing vesicles, we used 
two different approaches: (1) we transiently overexpressed the 
GFP-LC3 protein in HEK293- and MCF-7-DsRed-GABARAPL1 
cells and followed the intracellular localization of the two fusion 
proteins after treatment of the cells with lysosome inhibitors; 
(2) we stained the HEK293- and MCF7-Dsred-GABARAPL1 
cells with a specific lysosomal marker called Lysotracker green. 
When we expressed the GFP-LC3 in the DsRed-GABARAPL1-
expressing cell lines, we observed a diffuse localization of GFP-LC3 
throughout the cytoplasm and the nucleus and some punctate 
Figure 4. The GABARAPL1-ii form is associated with membranes in the cells. 
heK293-Flag:GABARAPL1:6 his cells were cultured in complete medium or DMeM 
supplemented with 1% FBs and 50 mM Nh4cl for 2 h. cells were then collected 
in PBs supplemented with 1 mM PMsF, washed, homogenized (WcL, Whole 
cell Lysates) and centrifuged for 10 min at 800 g. Following two ultracentrifuga-
tion rounds (30 min at 100,000 g), vesicles were resuspended in PBs (Pellet). The 
supernatant sample corresponds to the supernatant obtained after the first round 
of ultracentrifugation. One aliquot (20 µl) of each of the different fractions (WcL, 
supernatant and pellet) was separated on 15% sDs-PAGe followed by immunob-
lotting with anti-GABARAPL1 and anti-Transferrin receptor (Tfr, cD71) antibodies 
and detection with the ecL Plus reagent. A representative experiment of three 
performed is shown.
Figure 5. inhibition of lysosomal activity results in the accumulation of 
GABARAPL1-positive intracytoplasmic vesicles. McF-7 cells overexpress-
ing the DsRed-GABARAPL1 protein were incubated in complete me-
dium (control) (A and D), DMeM supplemented with 1% FBs and 50 mM 
Nh4cl for 2 h (Nh4cl) (B and e) or complete medium supplemented with 
500 nM of Bafilomycin A1 for 24 h (BafA1) (c and F). cells were then fixed 
and analyzed by confocal microscopy. The images on the right (D–F) 
correspond to a 3-fold magnification of the images on the left (A–c). 
Representative images of three independent experiments are shown.
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HEK293. When we treated the cells with NH
4
Cl or Bafilomycin 
A1 (Fig. 6D, G, M and P), we observed an almost complete 
relocalization of GFP-LC3 into intracytoplasmic vesicles in the 
two cell lines and an increase in DsRed-GABARAPL1 punctate 
structures but only part of those GABARAPL1-positive vesicles 
were LC3-positive as well (F, I, O and R). Since we observed a 
high heterogeneity of staining between cell lines and between 
cells from the same culture, we were unable to establish a sig-
nificant count of the number of vesicles carrying both LC3 and 
GABARAPL1. Nevertheless, we can affirm that not all vesicles 
are carrying both proteins. From preliminary counts, we could 
conclude that approximately 50–70% of vesicles in the MCF-7 
cells are double-stained and about 30–50% in the HEK293 
cells. Since LC3 has been described to be an autophagosome 
marker, we concluded that GABARAPL1 was partially located in 
autophagosomes. Following staining of the HEK293- or MCF7-
DsRed-GABARAPL1 cells with Lysotracker green, we observed 
that numerous but not all DsRed-GABARAPL1-positive vesi-
cles were stained with Lysotracker green (Fig. 7C and F). All 
together, these two experiments demonstrate that GABARAPL1 
can be localized in LC3-containing or Lysotracker green-stained 
intracellular vesicles. These results confirm that GABARAPL1 is 
associated with autophagic vesicles.
Intracellular punctate GABARAPL1 staining is abolished 
in Atg5-/- MEF. Previous publications raised some concern 
about the tendancy of the DsRed protein to form aggregates 
in the cells, structures which could be mistaken for intracel-
lular vesicles, resulting in misleading conclusions.35 To exam-
ine whether the punctate localization of GABARAPL1 in our 
stable cell lines was the result of DsRed aggregates or not, we 
transiently transfected WT and Atg5-/- MEF cells with a DsRed-
GABARAPL1-expressing vector and followed the localization 
structures in the cytosol. Regarding DsRed-GABARAPL1, the 
protein was localized in intracytoplasmic dots in MCF-7 and 
presented a diffuse localization with few punctate structures in 
Figure 6. GABARAPL1 partially colocalizes with Lc3 in the cells. McF7- (A–i) or heK293-DsRed-GABARAPL1 (J–R) cells were transfected with the pGFP-
Lc3 vector in Lab-TekTMii chambers. 48 h after transfection, cells were incubated with 50 mM Nh4cl for 2 h (D–F, M–O) or 500 nM Bafilomycin A1 for 24 
h (G–i, P–R). Living cells were then analyzed by confocal microscopy. Representative images of three independent experiments are shown.
Figure 7. GABARAPL1 is partially localized in lysosomes in the cells. 
heK293- (A–c) or McF7-DsRed-GABARAPL1 (D–F) cells were grown in 
Lab-TekTMii chambers for 24 h. cells were then incubated in complete 
medium supplemented with 50 nM Lysotracker green for 1 h and living 
cells were analyzed by confocal microscopy. Representative images of 
three independent experiments are shown.
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the autophagic process or inhibiting the lysosomal degradation. 
We incubated HEK293 cells overexpressing the GABARAPL1 
protein with: (1) lysosome inhibitors (NH
4
Cl, Bafilomycin A1 or 
E64d/PepstatinA), (2) autophagy inducers (rapamycin or EBSS), 
or (3) a combination of both. Subsequently, we searched for the 
modified form of the protein (GABARAPL1-II) in these cells. 
All of these treatments have been previously described to result in 
a significant increase in the amount of the phospholipid-linked 
forms of autophagy effectors such as LC3 and GABARAP. In 
our experiments, we effectively detected GABARAPL1-II but we 
observed variations in the amount of this form according to the 
protocol used. The highest levels were detected with NH
4
Cl. EBSS 
and rapamycin did not allow the detection of the form -II without 
the addition of lysosomal degradation inhibitors (Bafilomycin A1 
or E64d/PepstatinA). It is noteworthy that we obtained the same 
results with the stable MCF7-Flag:GABARAPL1:6 his cell line 
(data not shown). In conclusion, we show that GABARAPL1 is 
modified in the cells and that this modification is induced by 
autophagy inducers. These results are in agreement with the data 
obtained for the other members of the GABARAP family includ-
ing GABARAP, LC3 and GATE-16.36 The fact that this modi-
fication is only detected when the degradation of the forms -II 
are inhibited by lysosomal activity inhibitors is congruent with 
previously published data on LC3.26 Moreover, we clearly see in 
our experiment that the lipidation of LC3 is weak in the presence 
of the autophagy inducers alone compared to the levels detected 
after addition of lysosome inhibitors. Therefore, it seems that, in 
of the fusion protein before and after inhibition of lysosomal 
activity by NH
4
Cl or Bafilomycin A1 (Fig. 8). Former publica-
tions showed that the deletion of Atg5 abrogated the autophagic 
pathway in MEF cells.24 Our results demonstrated that, before 
treatment, the WT cells presented a high number of red vesicles 
whereas the Atg5-/- cells contained a very low number of these 
DsRed-GABARAPL1-stained vesicles. After incubation with 
lysosomal inhibitors, we detected an increase in the number of 
punctate structures in the WT cells (Fig. 8A–C), and a signifi-
cantly smaller increase in the Atg5-/- cell line (Fig. 8D–F). Taken 
together, our results demonstrate that the deletion of Atg5, and 
therefore the inhibition of the autophagic process, alters the for-
mation of DsRed-GABARAPL1-stained vesicles showing that 
these structures are not protein aggregates but rather related to 
the process of autophagy.
Discussion
Previous work has described the involvement of different 
GABARAP family members in the autophagic process. Atg8, 
LC3, GABARAP and GATE-16 have all been shown to be 
linked to phospholipids and recruited to autophagosomes after 
induction of autophagy.23 These effectors play an important role 
during the elongation of double-membraned structures leading to 
the sequestration of cytosolic constituents and to the formation 
of autophagosomes. After their completion, these vesicles fuse 
with lysosomes to induce the degradation and recycling of their 
contents.18 To our knowledge, all the data published to date show 
that these proteins play a role as effectors of autophagy but not 
as activators. Since GABARAPL1 (GEC1) shares a high iden-
tity with GABARAP as well as other members of the family, we 
asked whether GABARAPL1 might be implicated in this process 
as well. To examine this possibility, we addressed different ques-
tions: (1) Is GABARAPL1 cleaved in the cells to free the glycine 
116 residue at its C-terminal end?, (2) Is GABARAPL1 linked to 
phospholipids in the cells?, (3) Is GABARAPL1 delipidated by the 
autophagy-related cysteine protease Atg4B?, (4) Is GABARAPL1 
associated with intracellular vesicles?, (5) Does GABARAPL1 
relocalize to autophagosomes during the autophagic process?
First, we showed that a GABARAPL1-GFP fusion pro-
tein was cleaved to give two products, GABARAPL1 and GFP 
but that this cleavage was abolished when the glycine 116 resi-
due was replaced by an alanine. These results demonstrate that 
GABARAPL1 is processed in the cells and that the maturation 
occurs at glycine 116. Moreover, it is worth noting that we were 
unable to detect the GABARAPL1-GFP fusion protein in our 
cell lysates, suggesting that this protein was cleaved following its 
synthesis and that this maturation step was not a consequence 
of autophagy induction. In addition, similar data were obtained 
using GABARAP wild-type and mutant-expressing vectors in 
HEK293 (data not shown) and these results were confirmed, for 
the two proteins (GABARAPL1 and GABARAP), in different 
cell types (COS7, MCF-7) showing that this process is not cell-
type specific (data not shown).
We then asked whether GABARAPL1 was modified in the cells. 
To do so, we used a combination of different chemicals inducing 
Figure 8. intracellular punctate GABARAPL1 staining is abolished in 
Atg5-/- MeFs. WT (A–c) and Atg5-/- (D–F) MeF cells were transfected 
with a DsRed-GABARAPL1-expressing vector. 48 h after transfection, 
cells were incubated in complete medium (A and D), with 50 mM Nh4cl 
for 2 h (B and e) or 500 nM Bafilomycin A1 for 24 h (c and F). cells were 
then analyzed by confocal microscopy. Representative images of three 
independent experiments are shown.
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the number of intracellular GFP-GABARAPL1-positive vesicles 
and that a siRNA directed against Atg4B slightly diminished 
GABARAPL1 delipidation in the cells. However, in their experi-
ments, the authors used a polyclonal antibody raised against the 
full length protein GABARAPL1 but never demonstrated the 
specificity of this antibody by showing that it did not recognize 
GABARAP. The question of the specificity of this anti-GABA-
RAPL1 antibody would have to be addressed to draw any con-
crete conclusions about the identity of the protein detected in 
their immunofluorescence experiments.
To complement the previous results, we performed cell frac-
tionation experiments to determine whether GABARAPL1-II 
is associated with intracellular membranes after inhibition of 
the autophagic flow. Our data presented in Figure 4 displayed 
that the form -II of both GABARAP and GABARAPL1 were 
highly enriched in the membrane fraction compared to the lev-
els detected in the soluble fraction. It is worth noting that these 
results are similar to the ones previously published for LC3.43 
Nevertheless, it will be necessary in the future to develop a more 
accurate purification protocol to separate vesicles tagged with dif-
ferent proteins in order to determine if the two proteins can be 
co-purified in the same membrane fractions or if they are present 
in a different set of vesicles.
We additionally investigated whether the modification of 
GABARAPL1 in the cells was linked to a relocalization of the pro-
tein to intracellular vesicles after autophagy blockage. To address 
this question, we used two different stable cell lines, HEK293 and 
MCF-7 overexpressing the DsRed-GABARAPL1 protein. Using 
these cell lines, we observed that the untreated cells presented 
a GABARAPL1 punctate staining and that this vesicular local-
ization was enhanced after treatment with lysosome inhibitors 
demonstrating that GABARAPL1 accumulates in intracellular 
puncta after lysosomal inhibition. It is noteworthy that the orga-
nization of these dots was different according to the chemicals 
used. With NH
4
Cl, the puncta were localized throughout the 
cytoplasm whereas with Bafilomycin A1 they were concentrated 
in a cluster on one side of the nucleus. Such a staining pattern has 
already been described for lysosomes.30 Further experiments will 
be needed to determine if the puncta accumulating with the two 
chemicals represent identical vesicle population or if they differ. 
Former publications describe that NH
4
Cl action is linked to lyso-
somal activity whereas Bafilomycin A1 inhibits autophagosome/
lysosome fusion.30 These chemicals do not, therefore, target the 
same step in the autophagic pathway which might explain the 
difference in GABARAPL1 staining in the cells.
Consequently, we asked whether GABARAPL1 colocalizes 
with an autophagosome marker or is localized in acidic vesicles 
in the cells. For this purpose, we transfected HEK293- and 
MCF7-DsRed-GABARAPL1 cells with a GFP-LC3-expressing 
vector and visualized the localization of the two proteins after 
lysosome inactivation. The data obtained showed that a majority 
of vesicles, but not all, were double-stained for GABARAPL1 and 
LC3. The fact that these two proteins do not always colocalize 
can be explained in four ways: (1) a difference of expression of the 
two proteins in the cells, (2) the difference in stability between 
the GFP and DsRed fluorescence in acidic vesicles,35 (3) the fact 
our model, the conjugation of autophagy effectors to phospholip-
ids is a slower process than that of degradation.
We also observed that the levels of lipidation of the indi-
vidual Atg8 family members examined are different, with LC3 
presenting a higher rate of modification than the two other pro-
teins, GABARAP and GABARAPL1. These results were simi-
lar to those obtained in the MCF-7 cell line (data not shown). 
Nevertheless, since the affinity of the antibodies we used may 
vary from one form (-I) to another (-II), we cannot quantify the 
respective amounts of the -I and -II forms in the cells. Indeed, 
Mizushima and Yoshimori previously demonstrated that a spe-
cific LC3 antibody did not recognize the phospholipid-modified 
protein with the same affinity than the native one.37 They argued 
that a comparison of the ratio of conversion -I/-II between pro-
teins, conditions or cell types would be misleading.
We know that gabarapl1 transcripts are highly expressed in 
the brain and are more abundant than the lc3 ones.38 It has also 
previously been published that gabarapl1, lc3 and atg12 transcript 
expression is enhanced under cellular stress such as glucose depri-
vation by the FoxO transcription factors in cultured rat neonatal 
cardiomyocytes.39 Moreover, these increases of expression cor-
relate with an activation of the autophagic flux but the relative 
involvement of GABARAPL1 and LC3 in this process still has 
to be determined. In addition, the authors of the latter article did 
not demonstrate that the antibody used to detect GABARAPL1 
was specific to this protein and that the signals obtained were 
not linked to the expression of its homologue GABARAP. At 
the moment, with the tools available, it is therefore impossible 
to determine the relative role of each of the Atg8 family mem-
bers during the course of autophagy, since they are all involved 
in the same step of this process. One solution might be to cre-
ate knockout cell lines for each of these factors and study the 
behavior of the mutant cells throughout the course of autophagy, 
particularly during the formation of autophagosomes. In conclu-
sion, the tissue- or cell-specific expression of GABARAPL1 has 
still to be determined in order to study its relative involvement 
in autophagy as well as a comparison to the expression of the 
autophagic marker, LC3. These studies will, however, require 
a specific antibody. Nevertheless, we believe that the role of 
GABARAPL1 in autophagy is subtle and probably linked to a 
specific tissue such as the brain, where it is highly expressed, or to 
a specific autophagic process such as mitophagy.40
We then wondered whether the lipidation of GABARAPL1 
in the cells was a reversible mechanism, as it has already been 
described for LC3, GABARAP and GATE-16.18 To assess this 
question, we expressed the maturation/delipidating Atg4B 
enzyme in HEK293 cells overexpressing GABARAPL1 then 
blocked autophagosomal degradation to look for the phospholip-
id-linked form of GABARAPL1. Similar to the data obtained for 
GABARAP family members,41 we observed a significant decrease 
of GABARAPL1-II in the cells expressing Atg4B compared to 
the levels present in the untransfected cells. These results dem-
onstrate that Atg4B is able to delipidate GABARAPL1. The 
latter data obtained in the cellular context are congruent with 
those previously described in vitro.42 In the latter publication, 
the authors also showed that an overexpression of Atg4B reduced 
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86% identity at the amino-acid level. Recently published papers 
have used polyclonal anti-GABARAPL1 antibodies to detect 
the protein in immunofluorescence experiments. However, the 
question of specificity of these antibodies was not addressed and 
therefore the identity of the protein studied in these publications 
remains unclear.39,42 Consequently, apart from western blotting 
experiments in which we were able to differentiate between the 
two homologous proteins, we opted out of using our anti-GABA-
RAPL1 antibody for immunofluorescence experiments. The pro-
duction of a specific antibody directed against the GABARAPL1 
protein will be one of the next challenges before extending the 
study of this protein.
Using different experimental assays, we demonstrated in a 
multitude of ways that GABARAPL1 is implicated in the process 
of autophagy. Nevertheless, further experiments will be needed 
to explain the link between autophagy, GABARAPL1 and its 
function in vivo. In particular, it would be of great interest to 
study the relative involvement of the different members of the 
GABARAP family in the autophagic process. Are these proteins 
redundant in the cells or are they tissue specific? We know that 
numerous tissues co-express the GABARAP and GABARAPL1 
proteins but also that some tissues express one protein rather 
than the other.32,38 For example, gabarapl1 transcripts are much 
more abundant in the brain compared to lc3 and gabarap.38 Given 
the importance of autophagy in brain damage44 and neurode-
generative diseases,45 it will be essential to study the function 
of GABARAPL1 in the brain with respect to its implication in 
autophagy.
Materials and Methods
Reagents and antibodies. Cell culture reagents were purchased 
from Invitrogen (Carlsbad, CA). The following antibodies were 
used: polyclonal anti-GABARAPL1 (Chemicon Millipore, 
AB15278), polyclonal anti-LC3 (Novus Biologicals, NB100-
2220), polyclonal anti-GFP (Chemicon Millipore, AB3080), 
polyclonal anti-Transferrin receptor (CD71) (Santa Cruz, 
sc65882), monoclonal anti-Atg4B (Sigma, A2981) and polyclonal 
anti-Actin (Sigma, A5060). Bafilomycin A1 (Sigma, B1793) 
was prepared as a 1 mM stock in DMSO. Ammonium chloride 
(NH
4
Cl, Sigma, A0171) was prepared as a 0.5 M stock in H
2
O. 
Rapamycin (Sigma, R8781) was prepared as a 2.5 mM stock in 
DMSO. E64d and Pepstatin A (Sigma, E8640 and P5318) were 
prepared as 10 mg/ml stocks in DMSO. All other reagents were 
purchased from Sigma-Aldrich.
Plasmids and site-directed mutagenesis. The pcDNA3.1 
vector (Invitrogen, V795-20) was used for control transfec-
tions. The pcDNA5-FRT vector was purchased from Invitrogen 
(V6010-20). The pEGFP-C1 and pEGFP-N3 plasmids were 
obtained from Clontech (6084-1 and 6080-1). The pGFP-LC3, 
and pSF1-Flag(3X):hsAtg4B:Myc:6 his plasmids were kindly 
provided by Dr. Elazar (Weizmann Institute, Israël),22 and 
Dr. Yoshimori (Osaka University, Japan),23 respectively. The 
pGABARAPL1-GFP and pGFP-GABARAPL1 plasmids encod-
ing the Enhanced Green Fluorescent Protein (EGFP) fused to 
the N-terminus or C-terminus of the GABARAPL1 protein were 
that all autophagosomes might not be carrying both proteins, or 
(4) that GABARAPL1 may also be associated with a different set 
of vesicles not involved in the autophagic pathway. To answer this 
question, we stained HEK293- and MCF7-DsRed-GABARAPL1 
cells with a specific lysosomal marker, Lysotracker green. In this 
experiment, we did not use lysosomal inhibitors since Lysotracker 
green chemical is sensitive to pH changes. This double-staining 
experiment showed that the majority of GABARAPL1 colocal-
izes with the lysosomes but that GABARAPL1 can be also found 
outside of the lysosomes. All together, the latter data demonstrate 
that GABARAPL1 is predominantly localized in autophagosomes 
or lysosomes. These results are not surprising since autopha-
gosomes fuse with lysosomes to form autophagolysosomes and 
induce the degradation of their contents. Since GFP fluorescence 
is rapidly inhibited in acidic compartments, GFP-LC3 might 
allow the detection of early nonacidic autophagosomes whereas 
Lysotracker green stains late acidic vesicles.
These data are really interesting and will lead to some fol-
low-up experiments. Indeed, a recent publication described the 
interaction of LC3/GABARAP family members with the protein 
Nix involved in the clearance of damaged mitochondria by the 
autophagic pathway.40 The authors showed that GABARAPL1 
binds more strongly than other members of the family to Nix 
and that GABARAPL1 colocalizes with Nix in cells treated with 
a mitochondria poison. These results suggest that the clearance 
of damaged mitochondria may be mediated by the specific asso-
ciation between GABARAPL1 and Nix and therefore confer 
a specificity to the nonspecific autophagic process. In the near 
future, it will be of interest to determine whether the autophagic 
proteins of the LC3/GABARAP family have specific and differ-
ent cellular patterns, are linked to specific autophagic vesicles or 
if these proteins are involved in distinct autophagic degradation 
processes in the cells.
One main concern regarding the use of overexpression sys-
tems or exogenous protein expression is the fact that some pro-
teins can aggregate and therefore create intracellular punctate 
structures which might be mistaken for vesicles. To demonstrate 
that the GABARAPL1-containing dots observed in our experi-
ments were autophagy-related, we used the MEF Atg5-/- cell line 
defective for the autophagic pathway.24 When we expressed the 
DsRed-Protein in this cell line, we observed a very low number 
of intracellular red vesicles before or after treatment with NH
4
Cl 
or Bafilomycin A1 compared to the wild-type control cells. These 
results confirmed that the vesicles we observed are autophagy-
related or at least that their formation requires Atg5. The low 
number of vesicles still detectable in the Atg5-/- cells might be 
due to the role of GABARAPL1 as a transport protein38 but we 
also cannot completely rule out the idea that some aggregates are 
formed when using the DsRed protein as previously described.35 
Further experiments will be needed to assess this question.
In our study, we used transient transfection assays or designed 
stable cell lines overexpressing fusion proteins because we did not 
possess a specific anti-GABARAPL1 antibody. Indeed, all the 
homemade or commercial antibodies we have tested to date are 
not specific for GABARAPL1, as they detect the GABARAP pro-
tein as well.3,32 This is not surprising since the two proteins share 
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ammonium chloride,25 4 h in complete medium supplemented 
with 10 µg/ml E64d/PepstatinA26 or 24 h in complete medium 
supplemented with 500 nM Bafilomycin A1.27 For the induction 
of autophagy, cells were incubated for either 4 h in EBSS medium 
(Sigma, E3024) or 4 h in complete medium supplemented with 10 
µM Rapamycin. Treated or untreated DsRed- or GFP-expressing 
cells were then fixed with 2% paraformaldehyde (PFA, Sigma, 
P6148) in PBS for 15 min, washed thrice with PBS and analyzed 
using a fluorescence laser scanning confocal microscope Fluoview 
FV1000 (Olympus). Each picture corresponds to one example of 
a typical cell staining observed in six fields chosen at random. For 
the Lysotracker green staining, cells were grown in Lab-TekTMII 
chambers (Nunc, 155380) for 24 h and subsequently incubated in 
complete medium supplemented with 50 nM Lysotracker green 
(Invitrogen, L7526) for 1 h. Living cells were then analyzed by 
confocal microscopy as described above.
Cell fractionation. Cell fractionation was carried out 
essentially as described previously.28 In brief, HEK293-
Flag:GABARAPL1:6 his cells were cultured in complete medium 
or DMEM supplemented with 1% FBS and 50 mM NH
4
Cl for 
2 h to inhibit lysosomal activity. Cells were washed, collected 
in 1 ml PBS containing 1 mM phenylmethylsulfonylfluoride 
(PMSF, Sigma, 93482), homogenized by sonication (Sonics and 
Materials) and the large vesicles and nuclei were pelleted at 800 
g for 10 min. Supernatants were centrifuged at 100,000 g for 
30 min to harvest the membranes and intracellular vesicles and 
organelles. The pellets were resuspended in homogenization buf-
fer, sonicated once more and subjected to a second round of ultra-
centrifugation. Pellets were then resuspended in 1 ml PBS and 
one aliquot (20 µl) of the different fractions (Whole Cell Lysate, 
Supernatant of the first centrifugation and Pellet) were reserved 
for western blot analysis.
Western blot analysis. Cells were rinsed with ice-cold PBS 









) and lysed in a SDS-PAGE loading buffer (78 mM Tris-
HCl, pH 6.8, 2.5% SDS, 12.5%, 6.25% β-mercaptoethanol, 
0.025% bromophenol blue). Samples were sonicated for 30 s 
before loading (Sonics and Materials) and separated by SDS-
PAGE before transfer to Immobilon-P PVDF membrane 
(Dutscher, 44088). The membranes were blocked with 5% skim 
milk in 0.1% Tween 20/TBS (199 mM Tris-HCl, pH 7.4, 1.36 
mM NaCl, 0.1% Tween 20) and incubated with primary anti-
bodies in antibody block buffer (0.5% skim milk in 0.1% Tween 
20/TBS). The polyclonal anti-GFP, anti-GABARAPL1, anti-
LC3, anti-Actin and anti-Transferrin receptor (CD71) antibodies 
were diluted at 1:5,000, 1:2,000, 1:2,000, 1:2,000 and 1:1,000, 
respectively in the antibody block buffer. Immunoreactive bands 
were detected using goat horseradish peroxydase (HRP)-coupled 
secondary anti-mouse or anti-rabbit antibodies (1:20,000 in anti-
body block buffer) (PARIS, P1291) and the ECL Plus reagent 
(GE Healthcare Life Sciences, RPN2132), according to the man-
ufacturer’s protocol.
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Cell culture and transfection. The HEK293 and MCF-7 
cells (ATCC, CRL-1573 and HTB-22), WT and Atg5-/- MEF 
cells (kindly provided by Dr. Mizushima)24 were cultured in 
DMEM (Dulbecco’s Minimum Essential Medium, Invitrogen, 
11880) supplemented with 2 mM L-Glutamine (Invitrogen, 
25030-032), 100 µg/ml penicillin, 100 µg/ml streptomy-
cin (Invitrogen, 15140) and 10% foetal bovine serum (FBS, 
Invitrogen, 10270-106) in a 5% CO
2
 incubator at 37°C. The 
HEK293- and MCF7-Flag:GABARAPL1:6 his cell lines were 
maintained in the complete medium supplemented with 100 µg/
ml Hygromycin B (PAA, P02-015). The HEK293- and MCF7-
DsRed-GABARAPL1 cell lines were maintained in the complete 
medium supplemented with 100 µg/ml G418 (PAA, P02-012). 
Transient transfections were carried out using HEK293, MCF-7, 
WT and Atg5-/- MEF cells plated in 6-well plates (3 x 105 per 
well). 500 ng of pGFP-GABARAPL1, pGABARAPL1-GFP, 
pGABARAPL1-G116A-GFP, pGFP-LC3 or pDsRed-GABA-
RAPL1 and 1 µl TransFast reagent (Promega, E2431) were used 
per reaction according to the manufacturer’s protocol. To create 
the stable cell lines HEK293- or MCF7-Flag:GABARAPL1:6 
his, HEK293 or MCF-7 cells were plated in 10 cm-diameter 
culture dishes (106 per plate) and were transfected using 20 µg 
pcDNA5-Flag:GABARAPL1:6 his and 40 µl TransFast reagent 
per reaction, according to the manufacturer’s protocol. After 48 
h incubation, cells were split in two culture dishes and 400 µg/
ml Hygromycin B were added to the complete medium for the 
14 following days until the appearance of antibiotic-resistant 
single clones. The clones were then tested for the expression 
of the ectopic protein by western blotting using a polyclonal 
anti-GABARAPL1 antibody. To create the stable HEK293- or 
MCF7-DsRed-GABARAPL1 cell lines, HEK293 or MCF-7 cells 
were transfected using 20 µg pDsRed-GABARAPL1 and 40 µl 
TransFast reagent per reaction, according to the manufacturer’s 
protocol. 400 µg/ml G418 were added to the complete medium 
to select for single clones.
Autophagy and confocal microscopy. For the inhibition of lys-
osomal activity, cells cultured on glass coverslips were incubated 
for either 2 h in DMEM supplemented with 1% FBS and 50 mM 
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